Published in Cancer on March 15, 2010
Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 2.27
Integrin targeted therapeutics. Theranostics (2011) 1.36
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med (2011) 1.33
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr (2012) 0.99
Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv Drug Deliv Rev (2013) 0.89
Antiangiogenic therapy for glioma. J Signal Transduct (2012) 0.89
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
Recombinant disintegrin (r-Cam-dis) from Crotalus adamanteus inhibits adhesion of human pancreatic cancer cell lines to laminin-1 and vitronectin. J Venom Res (2015) 0.82
CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia (2014) 0.81
Antiproliferative effect of the jararhagin toxin on B16F10 murine melanoma. BMC Complement Altern Med (2014) 0.81
The role of integrins in TGFβ activation in the tumour stroma. Cell Tissue Res (2016) 0.80
Lunasin sensitivity in non-small cell lung cancer cells is linked to suppression of integrin signaling and changes in histone acetylation. Int J Mol Sci (2014) 0.79
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol (2011) 0.79
Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep (2015) 0.79
Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23. Immunology (2012) 0.76
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models. Oncotarget (2016) 0.76
Stromal Modulators of TGF-β in Cancer. J Clin Med (2017) 0.76
Ligand-induced Epitope Masking: DISSOCIATION OF INTEGRIN α5β1-FIBRONECTIN COMPLEXES ONLY BY MONOCLONAL ANTIBODIES WITH AN ALLOSTERIC MODE OF ACTION. J Biol Chem (2016) 0.75
Stromal characteristics may hold the key to mammographic density: the evidence to date. Oncotarget (2016) 0.75
(99m)Tc-3P-RGD2 molecular imaging targeting integrin αvβ3 in head and neck squamous cancer xenograft. J Radioanal Nucl Chem (2015) 0.75
The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice. Cancers (Basel) (2016) 0.75
The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer. Mol Pharmacol (2016) 0.75
Integrins in the Spotlight of Cancer. Int J Mol Sci (2016) 0.75
Inside the Cell: Integrins as New Governors of Nuclear Alterations? Cancers (Basel) (2017) 0.75
Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review. Cancers (Basel) (2017) 0.75
Integrin αvβ3 Signaling in Tumor-Induced Bone Disease. Cancers (Basel) (2017) 0.75
Integrins as Therapeutic Targets: Successes and Cancers. Cancers (Basel) (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem (2004) 2.90
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer (2009) 2.78
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Tradeoffs between income, biodiversity, and ecosystem functioning during tropical rainforest conversion and agroforestry intensification. Proc Natl Acad Sci U S A (2007) 2.71
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med (2002) 1.95
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res (2009) 1.90
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol (2007) 1.69
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant (2006) 1.63
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res (2005) 1.59
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res (2003) 1.59
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg (2003) 1.58
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg (2013) 1.50
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs (2009) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med (2010) 1.39
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol (2005) 1.37
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res (2007) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother (2008) 1.32
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol (2006) 1.31
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol (2008) 1.25
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24